Cargando…
Ivermectin for the Treatment of COVID-19 Disease: Too Good to Pass Up or Too Good to Be True?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344442/ https://www.ncbi.nlm.nih.gov/pubmed/34796243 http://dx.doi.org/10.1093/ofid/ofab318 |
| _version_ | 1783734474655137792 |
|---|---|
| author | Siedner, Mark J |
| author_facet | Siedner, Mark J |
| author_sort | Siedner, Mark J |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8344442 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83444422021-08-10 Ivermectin for the Treatment of COVID-19 Disease: Too Good to Pass Up or Too Good to Be True? Siedner, Mark J Open Forum Infect Dis Editorial Commentary Oxford University Press 2021-06-14 /pmc/articles/PMC8344442/ /pubmed/34796243 http://dx.doi.org/10.1093/ofid/ofab318 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Editorial Commentary Siedner, Mark J Ivermectin for the Treatment of COVID-19 Disease: Too Good to Pass Up or Too Good to Be True? |
| title | Ivermectin for the Treatment of COVID-19 Disease: Too Good to Pass Up or Too Good to Be True? |
| title_full | Ivermectin for the Treatment of COVID-19 Disease: Too Good to Pass Up or Too Good to Be True? |
| title_fullStr | Ivermectin for the Treatment of COVID-19 Disease: Too Good to Pass Up or Too Good to Be True? |
| title_full_unstemmed | Ivermectin for the Treatment of COVID-19 Disease: Too Good to Pass Up or Too Good to Be True? |
| title_short | Ivermectin for the Treatment of COVID-19 Disease: Too Good to Pass Up or Too Good to Be True? |
| title_sort | ivermectin for the treatment of covid-19 disease: too good to pass up or too good to be true? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344442/ https://www.ncbi.nlm.nih.gov/pubmed/34796243 http://dx.doi.org/10.1093/ofid/ofab318 |
| work_keys_str_mv | AT siednermarkj ivermectinforthetreatmentofcovid19diseasetoogoodtopassuportoogoodtobetrue |